Clinical Trial Update: A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

This clinical trial update reports results from a Phase I/Ib study of AZD9150 (ISIS-STAT3Rx) in patients with advanced or metastatic hepatocellular carcinoma. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AZD9150 (ISIS-STAT3Rx) (STAT3 antisense oligonucleotide)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic | Phase 1 | Status: COMPLETED | Results posted: 2017-03-06